Document is current
Any future updates will be listed below
-
Authors
Hadland, Brandon https://orcid.org/0000-0003-3999-9002
Varnum-Finney, Barbara
Dozono, Stacey
Dignum, Tessa
Nourigat-McKay, Cynthia
Heck, Adam M. https://orcid.org/0000-0002-2485-759X
Ishida, Takashi
Jackson, Dana L.
Itkin, Tomer
Butler, Jason M.
Rafii, Shahin https://orcid.org/0000-0001-5605-1067
Trapnell, Cole https://orcid.org/0000-0002-8105-4347
Bernstein, Irwin D. https://orcid.org/0000-0003-0795-3392
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (RC2DK114777, R01DK110563)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (K08HL140143)
American Society of Hematology (NA)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
- License Information
-
More Information
Article History
Received: 16 March 2020
Accepted: 9 February 2022
First Online: 24 March 2022
Competing interests
: B.H. and I.D.B. are inventors of a patent related to technology in this manuscript on the use of Notch agonists for expansion of embryonic HSC (US Patent # US10463698B2. Applicant: Fred Hutchinson Cancer Research Center, Seattle, WA, USA). I.D.B. owns shares in Deverra Therapeutics. The remaining authors declare no competing interests.
